ROYALTY PHARMA PLC CLASS A (RPRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RPRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RPRX | Independent Director; Chair | 68 | ["Former CFO, Wyeth","Leadership","Finance / Accounting","Business Strategy","Technology/Cybersecurity","Risk Management","Managing Director of G9 Capital Group LLC since January 2010","Member of the Investment Committee of Royalty Pharma (2014 to June 2020)","Various senior positions at Wyeth, including Chief Financial Officer from 1989 to 2010","Started career with Arthur Andersen & Company","Chair of Audit Committee","Selected for vast financial and accounting expertise","Broad knowledge of global business operations, finance, leadership, strategy and risk management","Qualified as an audit committee financial expert","financial expert","audit committee experience"] | ["Audit Committee","Nominating and Corporate Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PRAX | [] | ["Audit Committee"] | 2026 | ||
| ZTS | Former Chief Financial Officer of Wyeth; Independent Director; Chair | 68 | ["Former Chief Financial Officer of Wyeth","Over 20 years of leadership and financial management experience in global healthcare and pharmaceuticals","Exceptional financial and accounting expertise","Knowledge of reporting requirements and disclosure rules","Audit committee responsibilities","Institutional knowledge as chair of the Audit Committee","Expertise in working with internal and external audit teams","Navigating complex financial and compliance matters","Financially Literate","Audit committee financial expert"] | ["Audit","Corporate Governance","Audit Committee","Corporate Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Mr. Norden is the Managing Director of G9 Capital Group LLC, which invests in early-stage ventures and provides corporate finance advisory services, since January 2010. Gregory Norden was a member of the Investment Committee of Royalty Pharma from 2014 to June 2020. From 1989 to 2010, Mr. Norden held various senior positions at Wyeth, including Chief Financial Officer. Mr. Norden started his career with Arthur Andersen & Company. Other Public Company Directorships: Zoetis Inc. (2013-present) Praxis Precision Medicines, Inc. (2019-present) Former Other Public Company Directorships : NanoString Technologies, Inc. (2012-2024) Qualifications: Mr. Norden was selected to serve on our Board because of his vast financial and accounting expertise along with his extensive public company board experience. As former Chief Financial Officer of Wyeth, Mr. Norden has broad knowledge of global business operations, finance, leadership, strategy and risk management matters. Mr. Norden s qualification as an audit committee financial expert is critical as Chair of our Audit Committee.